Infliximab News and Research

RSS
Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.
Trial identifies a drug that may benefit some patients hospitalized with COVID-19 pneumonia

Trial identifies a drug that may benefit some patients hospitalized with COVID-19 pneumonia

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

Studies test intravenous immunoglobulin for treatment of Kawasaki disease and MIS-C

Studies test intravenous immunoglobulin for treatment of Kawasaki disease and MIS-C

Can targeting autophagy become a new approach to COVID-19 treatment?

Can targeting autophagy become a new approach to COVID-19 treatment?

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

Humoral and cellular response to COVID-19 vaccines in patients with IBD

Humoral and cellular response to COVID-19 vaccines in patients with IBD

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

Infliximab may hinder the effectiveness of some COVID-19 vaccines

Infliximab may hinder the effectiveness of some COVID-19 vaccines

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

NIH launches adaptive Phase 3 clinical trial to test immune modulator drugs in COVID-19 patients

NIH launches adaptive Phase 3 clinical trial to test immune modulator drugs in COVID-19 patients

New computational model can help determine drug viability

New computational model can help determine drug viability

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis – new treatments wanted

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Study identifies genetic marker which could personalize treatment for Crohn's disease

Study identifies genetic marker which could personalize treatment for Crohn's disease

Common genetic variant explains why immunotherapy often fails in Crohn's disease

Common genetic variant explains why immunotherapy often fails in Crohn's disease

New therapeutic target for rheumatoid arthritis and type 2 diabetes

New therapeutic target for rheumatoid arthritis and type 2 diabetes